home

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer ARNI, MDVN

Trendthelifesciencesreport2016-04-22 10:46 Read   83

Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with.

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse

Commentsthelifesciencesreport2016-04-22 10:37 Read   81

To treat chronic pain without risk of addiction is to straddle a knife's edge.

Cancer drugs help Roche beat expectations in first quarter

Commentspmlive2016-04-22 10:01 Read   73

Strong sales of Roche's top three drugs - backed up by strong growth for new launches - helped the Swiss pharma group top analyst projections in the first quarter.

Health Tip: Start Changing Your Lifestyle

Healthdrugs2016-04-22 09:57 Read   80

Making healthy lifestyle changes may involve a big commitment. But there are easy steps that can help you get going.

Common Class of Breast Cancer Drugs May Not Trigger 'Chemo Brain': Study

Trenddrugs2016-04-22 09:53 Read   90

THURSDAY April 21, 2016, 2016 -- Some breast cancer patients complain of a fogged mental condition often called "chemo brain," experienced after their therapy.

FDA bats back Sarepta’s counterattack as a final showdown looms over Duchenne drug

Regulatorfiercebiotech2016-04-22 09:48 Read   83

Sarepta’s regulatory team came out swinging after the FDA issued a harsh review of its Duchenne muscular dystrophy drug last January.

‘Toxic compound’ gains final blame in French trial disaster

EVENTSfiercebiotech2016-04-22 09:37 Read   88

The final regulatory report into a fatal French drug trial run by a drugmaker and its CRO partner earlier this year was "clearly linked to the compound tested"--but the report’s lead author claims common sense was lacking from researchers.

Allergan Acquires Topical Dermatology Company Topokine Therapeutics Adding Non-Invasive Fat Reduction Development Program

EVENTSprnewswire2016-04-22 09:31 Read   198

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction.

MedDay hails new progressive MS data as EMA filing beckons

Trendfiercebiotech2016-04-22 09:18 Read   90

French biotech MedDay has posted the full, follow-up data from two mid- to late-stage trials for its multiple sclerosis candidate, showing it has a long-term impact on reversing progression in the disease in a difficult-to-treat patient population.

MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab

TrendMorphoSys2016-04-22 09:13 Read   222

Bimagrumab Did Not Meet Its Primary Endpoint in Patients with sIBM

AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

TrendAbbVie2016-04-22 09:06 Read   85

The Netherlands and GHENT, Belgium, April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115.

Effective Disease Management of Ulcerative Colitis

Healthhealio2016-04-21 15:45 Read   88

Ulcerative colitis (UC) is the most common inflammatory bowel disease (IBD) worldwide, with approximately 600,000 Americans living with UC.